Your browser doesn't support javascript.
loading
Value of Doppler ultrasound scans in deciding whether to treat infantile haemangioma with oral propranolol.
Börjesson, C; Malloizel-Delaunay, J; Onnis, G; Mazereeuw-Hautier, J; Dreyfus, I.
Afiliação
  • Börjesson C; Department of Dermatology and Venereology, Reference Centre for Rare Skin Disorders, University Hospital of Toulouse, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse Cedex 9, France. Electronic address: clothilde.borjesson@gmail.com.
  • Malloizel-Delaunay J; Department of Vascular Medicine, University Hospital of Toulouse, 1, avenue Jean-Poulhès, TSA 50032, 31059 Toulouse Cedex 9, France.
  • Onnis G; Department of Dermatology and Venereology, Reference Centre for Rare Skin Disorders, University Hospital of Toulouse, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse Cedex 9, France.
  • Mazereeuw-Hautier J; Department of Dermatology and Venereology, Reference Centre for Rare Skin Disorders, University Hospital of Toulouse, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse Cedex 9, France.
  • Dreyfus I; Department of Dermatology and Venereology, Reference Centre for Rare Skin Disorders, University Hospital of Toulouse, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse Cedex 9, France.
Ann Dermatol Venereol ; 148(4): 233-237, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34218938
ABSTRACT

BACKGROUND:

Oral propranolol (Pr) must be administered until the end of the proliferation phase of infantile haemangioma (IH). This phase may be difficult to assess, particularly where a deep component is involved. Doppler ultrasound scans (DUS), which identify vascular activity (VA), could assist the clinician in making the correct therapeutic decision (CTD). PATIENTS AND

METHODS:

All children with IH treated with Pr for at least 3 months and up to the age of 9 months, and who also underwent DUS, were enrolled in this retrospective, single-centre, observational study. The quality of DUS as a binary diagnostic test for IH proliferation was assessed, together with its value in deciding whether to discontinue Pr (at the end of the presumed proliferation phase) or resume this drug (in the case of suspected recurrence).

RESULTS:

A total of 29 children were enrolled and 45 DUS were performed. Thirty-nine (87%) DUS were of high quality (80% sensitivity, 95% specificity) and made a major, moderate, or minimal contribution to the CTD in respectively 20%, 60% and 7% of cases.

DISCUSSION:

DUS proved to be a high-value tool. They were essential in some cases of IH, mainly periocular and localised forms, and those involving deep components, in which the question of discontinuing Pr arose (age>1 year) and where clinical examination had not been sufficient to make the CTD. Furthermore, in the vast majority of cases, they provide a helpful examination and complement clinical findings in terms of patient follow-up and reaching a CTD.

CONCLUSION:

DUS is an effective and complementary tool to clinical investigation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Propranolol / Hemangioma Capilar Tipo de estudo: Observational_studies / Prognostic_studies Limite: Child / Humans / Infant Idioma: En Revista: Ann Dermatol Venereol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Propranolol / Hemangioma Capilar Tipo de estudo: Observational_studies / Prognostic_studies Limite: Child / Humans / Infant Idioma: En Revista: Ann Dermatol Venereol Ano de publicação: 2021 Tipo de documento: Article